DNA Script awarded $5.5M in Innovation Grants From the European Comission and Bpifrance - Total financing to Date Is $24M New grants will accelerate DNA Script's commercialization of its novel high speed, high efficiency, free-of-harsh-chemicals DNA synthesis technology. Paris, France, April 4th 2018 -
DNA Script today announced awards totaling $5.5M in non-dilutive financing from the highly selective Horizon 2020 European Innovation Council
program of the European Commission and the Aide au développement de l'innovation
and Concours Mondial d'innovation
programs of Bpifrance. DNA Script was awarded this financing, to be received as subsidies and refundable advances, based on the promise of the company's innovative enzymatic DNA synthesis technology and the company's potential to become a global leader in DNA and RNA manufacturing.
As the field of genomics accelerates, innovative genome editing technologies are driving advancements in life sciences research. The market for synthetic nucleic acids has expanded to over $1 billion per year globally, but the demand is not always met. For the past 50 years, synthetic DNA has been manufactured through a complex chemical process with limitations in terms of quality, turn-around time and manufacturing flexibility. In contrast, DNA Script introduces a novel biochemical process for DNA and RNA synthesis based on the use of highly efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals.
"The team at DNA Script is extremely proud of this support from the European institutions and the French government through Bpifrance, which will aid in our goal of becoming a global leader in synthetic DNA manufacturing", said Thomas Ybert, PhD, CEO and co-founder of DNA Script. "We are excited about recent breakthroughs we have made with our technology platform, and these additional resources will allow us to further accelerate the development of the company."
"Through these funding packages, Bpifrance fulfills its mission of helping young and promising companies like DNA Script develop their technology in order to conquer new markets," said Adeline Kempf from Bpifrance. "We see in DNA Script a unique opportunity to create a new European leader in the life sciences — proof that the excellence of French research can be translated into commercial success." DNA Script is one of 57 companies to receive the very first award for small and medium-sized businesses given by the recently established European Innovation Council — a funding, advisory and networking arm of Horizon 2020 intended to support leading innovators, entrepreneurs, small companies and scientists with bright ideas and the ambition to scale up internationally. Horizon 2020 is the biggest EU research and innovation program ever created, with nearly €80 billion of funding available over 7 years (2014–2020). DNA Script was chosen for this award by a jury of innovators, entrepreneurs and venture capitalists after a competitive review process.
To date, DNA Script has raised a total of $24M. In September 2017, DNA Script announced Series A financing of $13 million led by Illumina Ventures, with additional investments from M Ventures — the corporate venture arm of Merck KGaA, Darmstadt, Germany — and existing investors Sofinnova Partners, Kurma Partners and Idinvest Partners. About DNA Script Founded in 2014 in Paris, DNA Script is the world's leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims to accelerate innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script's approach leverages billions of years of natural evolution to enable genome-scale synthesis. The company's technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemical production, improved crops and DNA data storage. www.dnascript.coAbout Bpifrance
A subsidiary of the Caisse des Dépôts (French Consignments and Loans Fund) and the State, a trusted partner of entrepreneurs, Bpifrance supports companies from start-up to stock exchange listing, with credit, collateral and equity. Bpifrance also provides support services and enhanced support for innovation, acquisitions and exports, in partnership with Business France. Bpifrance offers companies a continuum of funding at each key stage of their development and an offer adapted to regional specificities. With 47 regional offices (90% of its decisions are taken at the regional level) Bpifrance is a tool of economic competitiveness for entrepreneurs. Bpifrance supports public policies pursued by the French State and by Regional Councils to meet three objectives: support the growth of businesses; prepare future competitiveness; contribute to the development of a favorable ecosystem for entrepreneurship. With Bpifrance, companies benefit from an influential, available and effective intermediary to meet all their needs in terms of finance, innovation and investment.
For further information, please visit: www.bpifrance.fr About Horizon 2020
SME Instrument Phase 2 is part of Horizon 2020, a program managed by the European Commission and dedicated to innovation and research. It is part of the Industrial Leadership pillar of H2020 and seeks to support fast-growing, highly innovative SMEs with global, international ambitions. www.horizon2020.gouv.fr Press contact in the US
Lisa Rodriguez 415-505-5447 email@example.com Press contacts in Europe
Caroline Carmagnol and Tatiana Vieira
06 64 18 99 59 / 01 44 54 36 65 DNASCRIPT@alizerp.com DNA Script Contact
Sylvain Gariel, COO firstname.lastname@example.org